Rexinoid NEt-3IB Promotes Resident Macrophage Gene Expression and Mitigates Desiccation-Induced Ocular Surface Disease
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.4.31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2026. Verfasst von Jehan Alam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ocular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, United States. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Macrophages, Gene Expression Regulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the effects of rexinoid NEt-3IB on desiccating stress-induced dry eye, as well as monocyte/macrophage gene expression and cellular trajectory.
Methods
Eyes were topically treated with rexinoid NEt-3IB (5 µM) or vehicle three times a day for 5 days of desiccating stress-induced dry eye. Single-cell RNA sequencing (RNA-seq) profiled gene expression in conjunctival immune cells. RNA-seq was also used to evaluate gene expression in lipopolysaccharide (LPS)-stimulated, dexamethasone-treated (Dex, 1 µM), or NEt-3IB-treated (1-1000 nM) cultured monocytes. Cellular state trajectory and latent time were inferred with scVelo, and latent-time-associated genes were identified using Monocle 3. Permeability to Oregon Green-labeled dextran was used to assess corneal barrier, and conjunctival goblet cell parameters were measured in periodic acid-Schiff (PAS)-stained wholemounts.
Results
NEt-3IB significantly stimulated homeostatic, phagocytotic, and anti-inflammatory gene expression and suppressed inflammatory gene signatures in conjunctival monocyte/macrophage cells compared to vehicle (Padj < 0.05). Latent time trajectory analysis and flow cytometry further revealed that NEt-3IB preserved resident macrophage-associated gene and protein expression. Compared to vehicle, corneal labeled dextran uptake was lower (P = 0.001) and conjunctival goblet cell total (P = 0.001) and single-cell (P = 0.01) areas were higher in the NEt-3IB group. The impact of NEt-3IB on differentially expressed genes in cultured monocytes mirrored its effects in vivo. NEt-3IB and dexamethasone suppressed inflammatory mediator expression; however, NEt-3IB enhanced the expression of homeostatic factors, including Igf1 and Il10.
Conclusions
Rexinoid NEt-3IB suppresses inflammatory and stimulates homeostatic gene expression in the monocyte/macrophage lineage and desiccation-induced ocular surface disease. Rexinoid therapy may prove to be a novel approach to treat dry eye by stimulating endogenous production of homeostatic/anti-inflammatory factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ocular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, United States.
- Laboratory of Bioorganic and Medicinal Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Zitieren
APA
Alam, J., Qu, Y., Shao, J., Yaman, E., Zheng, K., Kakuta, H., & Pflugfelder, S. C. (2026). Rexinoid NEt-3IB Promotes Resident Macrophage Gene Expression and Mitigates Desiccation-Induced Ocular Surface Disease. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.4.31
Vancouver
Alam J, Qu Y, Shao J, Yaman E, Zheng K, Kakuta H, et al. Rexinoid NEt-3IB Promotes Resident Macrophage Gene Expression and Mitigates Desiccation-Induced Ocular Surface Disease. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.4.31
BibTeX
@article{Alam2026,
author = {Alam, Jehan and Qu, Yangluowa and Shao, Jianming and Yaman, Ebru and Zheng, Karen and Kakuta, Hiroki and Pflugfelder, Stephen C},
title = {Rexinoid NEt-3IB Promotes Resident Macrophage Gene Expression and Mitigates Desiccation-Induced Ocular Surface Disease},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.4.31}
}
EUVIMED